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RESEARCH
Factors associated with mortality in Scottish patients
receiving methadone in primary care: retrospective cohort
study
C McCowan, lecturer in health informatics,1 B Kidd, clinical senior lecturer in addiction psychiatry,2
T Fahey, professor of primary care medicine1,3
ABSTRACT
Objective To assess predictors of mortality in a
population of people prescribed methadone.
Design Retrospective cohort study.
Setting Geographically defined population in Tayside,
Scotland.
Participants 2378 people prescribed and dispensed
liquid methadone between January 1993 and February
2004.
Main outcome measures All cause mortality (primary
outcome) and drug dependent cause specific mortality
(secondary outcome) by means of Cox proportional
hazards models during 12 years of follow-up.
Results Overall, 181 (8%) people died. Overuse of
methadone (adjusted hazard ratio 1.67, 95% confidence
interval 1.05 to 2.67), history of psychiatric admission
(2.47, 1.67 to 3.66), and increasing comorbidity
measured as Charlson index ≥3 (1.20, 1.15 to 1.26) were
all associated with an increase in all cause mortality.
Longer duration of use (adjusted hazard ratio 0.95, 0.94
to 0.96), history of having urine tested (0.33, 0.22 to
0.49), and increasing time since last filled prescription
were protective in relation to all cause mortality. Drug
dependence was identified as the principal cause of
death in 60 (33%) people. History of psychiatric
admission was significantly associated with drug
dependent death (adjusted hazard ratio 2.41, 1.25 to
4.64), as was history of prescription of benzodiazepines
(4.35, 1.32 to 14.30).
Conclusions Important elements of care in provision of
methadone maintenance treatment are likely to
influence, or be a marker for, a person’s risk of death.
INTRODUCTION
Drugmisuse is amajor public health problem through-
out the United Kingdom and elsewhere. In Scotland,
10 798 people presented to drug misuse agencies in
2002, half of whom were in their 20s.1 2 Similarly, in
the United States, more than three million people are
estimated to have used heroin, and 200 000 people are
estimated to be engaged with opiate treatment
programmes.3Drugmisusers have an annualmortality
six times higher than that for a general, age matched
population, and more than two thirds of these deaths
are due to drug overdoses.4
To combat this public health problem, methadone
maintenance programmes have been started on the
basis of evidence from randomised trials that metha-
done decreases illicit drug use, reduces injecting beha-
viour leading to a decrease in transmission of viral
infections such as HIV and hepatitis, reduces the risk
of opioid related deaths, improves physical andmental
health, and is associated with a decrease in criminal
activity.5-7 In the UK, methadone treatment for heroin
addiction is largely provided by general practitioners
—the “British system”—and prescribing of methadone
in primary care substantially increased throughout the
1990s.8 9 The central ethos of this approach is one of
harmminimisation, and other countries are expanding
provision ofmethadone treatment into primary care in
a similar way.3 10
However, treatment with methadone in primary
care has been described as a “double edged sword”
because methadone itself is associated with drug
related deaths.11 A confidential inquiry into metha-
done related deaths carried out in Scotland in 2000
showed an 18% year on year increase in the number
of prescriptions for methadone since 1996.12 Fifty six
drug related deaths took place in 2000 and were
referred to the inquiry; in 30 (54%) cases, methadone
was cited on the death certificate.12 Because of the
annual increase in the number of prescriptions for
methadone, although the proportion of methadone
related deaths is declining, methadone related deaths
still represent an important public health problem.912 13
Methadone related deaths seem to be due to an inter-
action of patient related and organisational factors:
drug dosing, concurrent use of other drugs, and defi-
ciencies in the monitoring and delivery of methadone
care programmes.7 14
Because of the risks and benefits of methadone treat-
ment in the community, guidance on prescription,
monitoring, and dispensing arrangements for metha-
done has evolved alongside a postgraduate training
programme sponsored by the Royal College of Gen-
eral Practitioners Substance Misuse Unit.15 Formal
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structured psychosocial support is recommended
alongside explicit pharmacological support: super-
vised consumption, clarity about maintenance or
detoxification, and optimal dose ranges for
maintenance.15 However, evidence based guidance of
this sortwas not available to general practitioners in the
mid-1990s.
In this study, we aimed to examine the interaction of
patient related factors and prescribing factors at the
individual level and assess their independent impact
on the risk of both all cause mortality and drug depen-
dent cause specific mortality in a primary care setting
in a defined geographical population.
METHODS
Study design and patients
We identified people resident in Tayside, Scotland,
who were registered with a general practitioner and
were prescribed and dispensed liquid methadone
between January 1993 and February 2004. Every per-
son registered with a general practitioner in Tayside is
assigned a 10 digit unique patient identifier, the Com-
munity Health Index number used in all encounters
with the NHS. This number, which includes the per-
son’s date of birth, allows linkage of health related
datasets, providing a unique resource combining infor-
mation on dispensed prescribing with detailed clinical
data at the level of the individual patient.
Procedures
We collected data on age, sex, and postcode for each
patient who was dispensed a liquid methadone pre-
scription from the Community Health Index number
register. We used the number to link these records to
all dispensed prescribing and to standard morbidity
register records for admission to hospital or to a psy-
chiatric unit. In addition, we made linkages to General
Register Office mortality data and to laboratory data-
sets relating to urine testing for opiates andother drugs.
We followed standard operating procedures at the
Health Informatics Centre, University of Dundee, to
ensure anonymisation of the dataset (www.dundee.ac.
uk/hic/).
We used census data from 2001 to calculate a Car-
stairs score and subsequent category for socioeco-
nomic status for each person on the basis of their home
postcode.16Wederived aCharlson comorbidity index,
which is a validated prognostic indicator for comorbid-
ity, from each person’s standard morbidity register
record by using the ICD-9 and ICD-10 (international
classification of diseases, ninth and 10th revisions)
codes in the hospital admission records.17 18 We also
examined the encashed prescribing records and
flagged the Charlson disease groups for people who
were receiving drugs for respiratory disease, AIDS,
peptic ulcers, cancer, metastatic tumours, diabetes,
myocardial infarction, connective tissue disorders,
and dementia. We categorised Charlson index scores
into three groups with low (0), medium (1 to 2), and
high (≥3) morbidity.
Each record of a prescription for methadone con-
tained details on the patient’s Community Health
Indexnumber; thedate of prescription; thedose, quan-
tity, strength, and type of methadone; and the general
practitioner and practice where the prescription was
issued. We calculated the length of methadone treat-
ment from the number of days between the first and
last prescriptions and the coverage of the last prescrip-
tion.We calculated the mean dose of methadone from
the total days’ coverage for each person (number of
days at prescribed amount for each prescription) and
the total amount prescribed.We categorised people as
overusing methadone if the length of treatment was
shorter than the total coverage of the prescribed pre-
scriptions. We flagged patients as “on treatment” if
their last methadone prescription was within three
months of their date of death or the end of the study
period. We defined a “break” in methadone treatment
if a discontinuation in prescription of methadone of
90 days ormore occurred. In accordance withUKpre-
scribing recommendations, we categorised people
who were below, within, and above the recommended
methadone maintenance range of 60 mg to 120 mg
daily, and fitted this as a binary variable with ≥60 mg
as the cut-off point.19
We examined prescribing records for other drugs
and recorded any patient who was prescribed a drug
from the hypnotic or anxiolytic class as receiving ben-
zodiazepines. We recorded drugs used for psychoses
and related disorders as antipsychotics and also
recorded use of antidepressants and opioid analgesics.
We calculated the total number of prescriptions
issued fromeach practice from the prescribing records.
We then grouped practices into quarters on the basis of
the number of methadone prescriptions issued and
assigned each person the value for the last practice to
issue methadone. We included this variable in the sur-
vival analysis to represent the volume of methadone
prescribing by practice.
Our main outcome measure was all cause mortality
recorded on the General Registry Office death certifi-
cate or on the Community Health Index number reg-
ister held by Tayside Health Board.
Year
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Secular trends showing deaths and prescription items for methadone, Tayside 1993-2003.
Two deaths and 2116 prescription items for methadone occurred in the period January to
February 2004—data included in overall analysis but not presented in figure
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Statistical analysis
We report data statistics as number (percentage) of
people for categorical variables and mean (SD) for
continuous variables. Continuous variables that do
not follow a normal distribution were tested with the
Shapiro-Wilks test for skewness and reported as the
median and interquartile range. We report χ2 tests for
trend for differences in distribution of the population.
We used Cox proportional hazards models to esti-
mate hazard ratios and 95% confidence intervals for
each unadjusted and adjusted covariate in relation to
all cause mortality and cause specific mortality. We
included covariates in the multivariate model if we
deemed them to be of clinical significance or if they
had a univariable P value below 0.2. We assessed the
proportional hazards assumption by using trend tests
of the Schoenfeld residuals; those that failed the
assumption or were deemed to be time dependent
were entered as continuous time dependent
covariates.20 Hazard ratios for variables treated as
time dependent covariates vary over time, sowe report
them at the median follow-up time. We followed up
patients until time of death or the end of the study per-
iod. We used Stata version 9 for all statistical analyses.
Sample size
Our sample size calculation assumed an estimate of
multiple drug use of 65% in drug related fatalities,4
enabling us to detect a difference of 13% between
those who died from methadone and comparators
who did not die while takingmethadone with a sample
size of 1500 people (120 deaths with 82% power, 150
deaths with 90% power, and two sided 5% significance
level).
RESULTS
Descriptive statistics
A cohort of 2378 people were prescribed and dis-
pensedmethadone during the 12 year study—a total of
12 037 person years with a median follow-up of 4.38
(interquartile range 1.92-8.12) years. Table 1 shows
the descriptive statistics for the cohort. Sixty five per
cent were aged under 30 years, and more than half
were from the lowest socioeconomic groups (Carstairs
categories 6 and 7). More than 40% of patients were
prescribed methadone for more than three years;
1233 (52%) were still on treatment at the end of fol-
low-up, which was either the date of death or the end
of the study.
Almost half of the cohort had a record of psychiatric
admission on the standard morbidity register, and co-
prescription of benzodiazepines, antipyschotics, anti-
depressants, and opioid analgesics was high (table 1).
Almost four fifths of the patients had at least one urine
test, and aminority had evidence of taking ameandose
ofmethadonehigher than that recommended (table 1).
The mean dose of methadone calculated across each
person’s prescriptions ranged from 1.7 mg to 200 mg.
Themean dose was lower than the recommended ade-
quate maintenance range of 60-120 mg daily for 2023
(85%) people, within this range for 349 (15%) people,
and above 120 mg for six people. The median indivi-
dual mean dose was 40 (interquartile range 28-51) mg.
Table 1 | Characteristics of cohort, according to whether patients were alive or died. Values
are numbers (percentages)
Characteristics
Patients alive who
took methadone
(n=2197)
Patients who died
taking methadone
(n=181) Total (n=2378)
Male 1462 (67) 127 (70) 1589 (67)
Age (years):
16-19 241 (11) 9 (5) 250 (11)
20-29 1230 (56) 87 (48) 1317 (55)
30-39 517 (24) 56 (31) 573 (24)
40-60 209 (10) 29 (16) 238 (10)
Social class (Carstairs):
1 27 (1) 4 (2) 31 (1)
2 131 (6) 3 (2) 134 (6)
3 305 (14) 21 (12) 326 (14)
4 207 (9) 15 (8) 222 (9)
5 407 (19) 29 (16) 436 (18)
6 608 (28) 63 (35) 671 (28)
7 490 (22) 42 (23) 532 (22)
Comorbidity (Charlson index):
0 1982 (90) 96 (53) 2078 (87)
1-2 157 (7) 27 (15) 184 (8)
≥3 58 (3) 58 (32) 116 (5)
Mean methadone dose:
<60 mg 1878 (85) 145 (80) 2023 (85)
60-120 mg 345 (16) 36 (20) 381 (16)
≥120 mg 6 (<1) 0 (0) 6 (<1)
Overusing methadone 119 (5) 29 (16) 148 (6)
Methadone breaks:
0 1019 (46) 108 (60) 1127 (47)
1 554 (25) 46 (25) 600 (25)
2-3 488 (22) 21 (12) 509 (21)
≥4 136 (6) 6 (3) 142 (6)
Duration of methadone treatment:
<6 months 445 (20) 51 (28) 496 (21)
6 months to 1 year 212 (10) 21 (12) 233 (10)
1-2 years 385 (18) 24 (13) 409 (17)
2-3 years 195 (9) 19 (11) 214 (9)
>3 years 944 (43) 63 (35) 1007 (42)
Time since last methadone
prescription filled:
≤1 month 835 (38) 94 (52) 929 (39)
2-3 months 281 (13) 23 (13) 304 (13)
4-6 months 207 (9) 9 (5) 216 (9)
>6 months 874 (40) 55 (30) 929 (39)
Psychiatric admission 1025 (47) 139 (77) 1164 (49)
Urine tests 1764 (80) 93 (51) 1857 (78)
On treatment at end of follow-up 1116 (51) 117 (65) 1233 (52)
Co-prescribing:
Benzodiazepines 1634 (74) 160 (88) 1794 (75)
Antipsychotics 451 (21) 33 (18) 484 (20)
Antidepressants 1051 (48) 80 (44) 1131 (48)
Opioid analgesics 831 (38) 99 (55) 930 (39)
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Cause of death and methadone prescriptions over time
During the 12 year study period, 181 (8%) people died.
The number of deaths remained constant despite the
increase inmethadone prescription items from 5852 in
1993 to 16 379 in 2003, the last full year for which data
were available (figure). Cause of death was available in
166 (92%) of these people from their General Registry
Office record. The remaining 15 people were identi-
fied as dead from the Community Health Index num-
ber register, but as no General Registry Office record
was available we could not ascertain cause of death.
Codes that relate to “drug dependence”were recorded
as the principal cause in 60 (33%) people. Table 2 sum-
marises the other principal causes of death.
Univariable and multivariable associations with all cause
mortality
After adjustment for significant covariates, increasing
comorbidity, overuse of methadone higher than
recommended, and history of psychiatric admission
were all associated with an increase in all causemortal-
ity (table 3). Longer duration of methadone use,
increasing time since last methadone prescription was
filled, and history of having urine testing were protec-
tive in relation to all cause mortality, but “breaks” in
receiving methadone and co-prescription of drugs
were not associated once fitted to the multivariable
model (table 3). Variables not included after unad-
justed analysis were male sex, use of benzodiazepines,
and volume of methadone prescribing by practice.
Univariable and multivariable associations with cause
specific mortality
When we assessed the 60 (33%) people who had a
“drug related” death attributable on theirGeneral Reg-
istry Office death certificate, the same explanatory
variables that were protective in relation to all cause
mortality persisted—namely, longer duration of
methadone use, increasing time since last methadone
prescriptionwas filled, and history of having urine test-
ing (table 4). Similarly, history of psychiatric admis-
sion remained independently associated with
increased risk of drug dependent cause specificmortal-
ity. Of note, co-prescribing of benzodiazepines was
now strongly associated, whereas prescription of
antidepressants and antipsychotics seemed to be pro-
tective in relation to drug related death (table 4).
DISCUSSION
This primary care based study has characterised the
population of people engaged with a methadone pro-
gramme as being predominantly young men from a
lower socioeconomic background.21 22 Psychiatric
admission in the 12 years of follow-up occurred in
almost half the cohort, co-prescribing of benzodiaze-
pines occurred in three quarters of the cohort, and co-
prescribing of antidepressants occurred in half. The
population could thus be classified as a vulnerable
and deprived group.
The overall mortality of 8% in the cohort during the
12 year study period is slightly above the annual mor-
tality rate of four to five per 100 000 described in a
previous Scottish study.12 Clear signals emerge in rela-
tion to safe prescribing and monitoring of methadone
maintenance treatment in primary care, but caution is
needed in that these associations may not be causal
because of the nature of this observational study.23
Overuse of methadone may be a marker of less rigor-
ous follow-up and communication between prescrib-
ing general practitioners and dispensing community
pharmacists. Alternatively, overuse may be a marker
for people who have dispersed the drug to others. UK
guidance emphasises that methadone maintenance
treatment needs a coordinated multidisciplinary
approach.19 24 Although only a relatively small propor-
tion of the people used a higher than recommended
dose of methadone, their relative risk of death was
more than one and a half times that of people who
took the correct dosage. Not unexpectedly, comorbid-
ity remains an independent risk factor in relation to all
causemortality in the cohort, and the strongest associa-
tionwas for patientswith ahistory of psychiatric admis-
sion (table 3). In terms of protective factors, longer
duration of treatment, increasing time since lastmetha-
done prescription, and a history of involvement in
urine testing programmes (irrespective of the result)
were associated with a reduced risk of all causemortal-
ity. These are likely to be markers of people who are
stabilised on maintenance treatment and engaged in
monitoring procedures or who have successfully com-
pleted a methadone treatment reduction programme.
We found substantial under-dosing with metha-
done; 84% of the cohort were receiving a mean dose
that was less than the recommended 60-120 mg
advised by UK Advisory Council on the Misuse of
Drugs and National Institute for Health and Clinical
Excellence (NICE).19 24 This finding is consistent with
comparative data in other countries.25 Commentators
suggest that some proponents of methadone are strong
advocates of higher doses of methadone in terms of
retention and reduction of heroin usage.26 Evidence
from randomised controlled trials comparing different
methadonedosages supports this view, but the findings
in relation to mortality from overdose, although
favouring higher doses of methadone (>75 mg daily
versus 5-55 mg daily), are based on a very small
Table 2 | Documented cause of death from General Registry
Office (GRO) death certificate (n=166)
Recorded cause of death No (%)
Drug dependence/related 60 (36)
Endocarditis, cardiovascular 11 (7)
HIV related 14 (8)
Cancer 20 (12)
Pneumonia and related 5 (3)
Accidents, trauma, self harm 13 (8)
Liver disease, hepatitis C 9 (5)
Other 34 (20)
15 patients were identified as dead from Community Health Index
number register, but as no GRO record was available cause of death
could not be ascertained.
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number of deaths (one death in high dose versus four
deaths in low dose groups).27 More research is needed
in relation to the risks and benefits of a low dose versus
high dose approach to methadone maintenance in
terms of retention and risk of overdose.
More than a third of the cohort who died had a prin-
cipal cause of death attributed to a drug related cause.
A different picture emerges in relation to individual
and organisational risk factors in terms of drug depen-
dent cause specific mortality (table 4). Co-prescription
of benzodiazepines had the strongest association with
drugdependent death, historyof psychiatric admission
remained an independent risk factor, and co-prescrib-
ing of antipsychotics and antidepressants was indepen-
dently protective.Markers of stability withmethadone
or cessation of methadone remain protective—history
of urine testing and time since lastmethadone prescrip-
tion was filled (table 44). These findings are important
to community based methadone programmes. As
NICE guidelines acknowledge, 24 most randomised
controlled trials of methadone in the treatment of
drug dependence were done in outpatient or inpatient
settings or specialist treatment centres. This commu-
nity based study gives a clear indication of the prescrib-
ing,monitoring, andmanagement of these patients and
the subsequent impact on all cause anddrugdependent
mortality.
The unique nature of this dataset in terms of record
linkage provides evidence that recommendations on
best practice improve patients’ outcomes and that the
improvements that have taken place in terms of the
delivery of methadone maintenance programmes in
the UK are likely to reduce the risk of death in this
vulnerable group of people.8 28 This study also pro-
vides evidence about subgroups of people, particularly
thosewith a history of psychiatric admission,who have
a higher risk of death. Similarly, for general practi-
tioners who are prescribing methadone, monitoring
of urine and avoidance of co-prescribing of benziodia-
zepines should be implemented.The findings from this
study emphasise the need for a psychosocial perspec-
tive in relation to ongoing management of people
enrolled in methadone maintenance programmes. In
some situations, people at higher risk (history of psy-
chiatric illness, poor engagement with services includ-
ing urine testing) might be more appropriately
managed in a specialist, rather than a generalist, envir-
onment.
To avoidmethadone related deaths and improve the
quality of methadone prescribing, the UK Advisory
Council on the Misuse of Drugs has produced guide-
lines that recommend a structured delivery of service
with clear roles and responsibilities, particularly for the
prescribing doctor, alongside psychosocial care.11 29 By
providing clear and explicit recommendations about
the prescribing and dispensing of methadone, in con-
junction with an organised system of delivery, drug
related mortality and morbidity are expected to be
reduced.14 30 However, commentators acknowledge
that many of the recommendations in the guidelines
are “very loosely evidence-based,”14 and quality mar-
kers associated with the prescribing and delivery of
methadone need to be validated and related to indivi-
dual outcomes. The results of this cohort study provide
evidence of the value of stabilised prescribing, regular
monitoring of urine, and avoidance of co-prescribing
of benzodiazepines when possible.
Context of other studies
In the context of other studies, our findings are consistent
with the demographic pattern of drug related deaths
occurring in young, socially deprivedmen.2122 The find-
ings in relation to all cause mortality are consistent with
the high mortality described in the drug outcomes
research in Scotland (DORIS) study.31 Although a rela-
tively small proportion of the Tayside population were
prescribed methadone, the proportion who died during
the follow-upperiodwas substantial. The applicability of
our findings in terms of methadone maintenance pro-
grammes in primary care is therefore likely to be robust.
Table 3 | Univariable and multivariable associations between covariates and all cause
mortality
Cohort characteristic
Unadjusted hazard ratio
(95% CI)
Adjusted hazard ratio
(95% CI)
Male sex 1.06 (0.77 to 1.45) NA
Age (per year) 1.04 (1.02 to 1.05)* 1.00 (0.98 to 1.01)
Social class (Carstairs):
1 (reference category) 1.0 1.0
2 0.16 (0.04 to 0.73)* 0.18 (0.04 to 0.82)*
3 0.48 (0.16 to 1.40) 0.52 (0.17 to 1.54)
4 0.49 (0.16 to 1.49) 0.45 (0.15 to 1.41)
5 0.41 (0.14 to 1.17) 0.36 (0.12 to 1.04)
6 0.62 (0.22 to 1.70) 0.46 (0.16 to 1.28)
7 0.54 (0.19 to 1.51) 0.52 (0.18 to 1.76)
Comorbidity (Charlson index):
0 (reference category) 1.0 1.0
1-2 2.85 (1.86 to 4.37)* 1.08 (1.02 to 1.14)*†
≥3 6.58 (4.72 to 9.19)* 1.20 (1.15 to 1.26)*†
Mean methadone dose ≥60 mg 1.54 (1.07 to 2.23)* 0.93 (0.62 to 1.39)
Overusing methadone 3.12 (2.09 to 4.64)* 1.67 (1.05 to 2.67)*
Methadone breaks 0.58 (0.50 to 0.67)* 0.93 (0.78 to 1.10)
Duration of methadone treatment (years) 0.78 (0.75 to 0.82)* 0.95 (0.94 to 0.96)*†
Timesince lastmethadoneprescription filled (months):
≤1 (reference category) 1.0 1.0
2-3 0.77 (0.49 to 1.22) 0.97 (0.91 to 1.02) †
4-6 0.66 (0.33 to 0.1.30) 0.91 (0.84 to 0.99)* †
>6 0.45 (0.32 to 0.62)* 0.70 (0.66 to 0.73)* †
Psychiatric admission 2.46 (1.74 to 3.49)* 2.47 (1.67 to 3.66)*
Having urine tested 0.31 (0.23 to 0.41)* 0.33 (0.22 to 0.49)*
Co-prescribing:
Benzodiazepines 1.18 (0.74 to 1.86) NA
Antipsychotics 0.77 (0.53 to 1.12) 0.85 (0.56 to 1.29)
Antidepressants 0.76 (0.56 to 1.01) 0.80 (0.57 to 1.44)
Opioid analgesics 1.33 (0.99 to 1.79) 1.17 (0.84 to 1.64)
Final regression model mutually adjusted for all significant covariates; male sex, use of benzodiazepines, and
volume of methadone prescribing by practice were assessed unadjusted but had no significant influence (P>0.2)
and so were excluded from final model.
NA=not applicable.
*P<0.05.
†Variable treated as time varying coefficient in Cox regression model and hazard ratio reported at median
follow-up of 4.38 years.
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Co-prescribing of benzodiazepines was associated with
drug related death, which supports findings that these
substances, along with alcohol, are commonly found in
subsequent toxicological reports of drug related
deaths.21 Previous UK research showed that people pre-
scribed methadone as well as benzodiazepines were at
greater risk of overdose than patients taking methadone
alone.32Moredetailed toxicology reportswere not avail-
able, and we are unable to report on this. Nevertheless,
the high proportion of co-prescribing of benzodiaze-
pines throughout the study period, combined with its
association with drug related death, is a troublesome
finding.
Limitations of study
This study has some shortcomings. The significant
association of a mean dose of methadone higher than
that recommended with all cause mortality could be
attributed to factors other than use of a higher dose of
methadone in itself—for instance, it could be a marker
formore chaotic drug using behaviour or dispersion of
methadone. Furthermore, in observational studies of
this sort, the possibility of residual confounding may
remain a problem; caution is neededwhen interpreting
the association of organisational and prescribing fac-
tors with all cause and drug dependent cause specific
mortality, and these associations should be viewed
principally as hypothesis generating.We could not col-
lect data on cause of death for 15 (8%) of the total
cohort who died and acknowledge that documented
cause of death may have been difficult to ascertain or
attribute for some people. Other shortcomings of the
study relate to the limited details of practice arrange-
ments regarding initial assessment, supervised con-
sumption, and counselling arrangements. As a
previous national study of drug related deaths found,
the completeness of primary care records in relation to
antecedent management is often poor.24 Lastly, our
cut-off point of three months or more since the filling
of the last prescription is likely to be conservative—
many people will have stopped taking methadone by
this time.
Implications for methadone programmes
This cohort did not have a record of psychological,
quality of life, or other patient centred indices of well-
being. Other community based studies have inter-
viewed participants and obtained these types of data,
albeit in a more selected sample.33 34 The interaction of
psychological wellbeing, history of psychiatric admis-
sion, and the impact of psychosocial support alongside
methadone prescribing and monitoring needs further
study. In terms of improving the delivery of metha-
done maintenance programmes in primary care,
paper based guidance may no longer be sufficient.
Health information technology systems have been
shown to improve quality of care by increasing adher-
ence to guideline based recommendations, enhancing
surveillance and monitoring, and decreasing the inci-
dence of drug errors.35 Similarly, computerised clinical
decision support systems that are focusedmore on clin-
ical decisionmaking and provide support on drug pre-
scribing (dose, duration, and appropriateness), drug
monitoring, and drug interactions may have a role.
Table 4 | Univariable and multivariable associations between covariates and drug dependent
cause specific mortality
Cohort characteristic
Unadjusted hazard ratio
(95% CI)
Adjusted hazard ratio
(95% CI)
Male sex 1.24 (0.70 to 2.21) NA
Age (per year) 0.98 (0.95 to 1.01) 1.00 (0.98 to 1.01)
Social class (Carstairs):
1-4 (reference category) 1.0 NA
5-7 1.12 (0.63 to 2.02) NA
Mean methadone dose ≥60 mg 0.68 (0.29 to 1.58) NA
Overusing methadone 4.52 (2.47 to 8.26)* 1.85 (0.91 to 3.80)
Methadone breaks 0.51 (0.39 to 0.68)* 1.01 (0.74 to 1.40)
Duration of methadone treatment (years) 0.76 (0.69 to 0.83)* 0.93 (0.92 to 0.95)*†
Timesince lastmethadoneprescription filled (months):
≤1 (reference category) 1.0 1.0
2-3 0.52 (0.22 to 1.24) 0.64 (0.26 to 1.04)
4-6 0.40 (0.10 to 1.67) 0.24 (0.06 to 1.01)
>6 0.34 (0.19 to 0.62)* 0.02(0.00 to 0.05)*
Psychiatric admission 2.23 (1.22 to 4.07)* 2.41 (1.25 to 4.64)*
Having urine tested 0.27 (0.16 to 0.45)* 0.52 (0.26 to 1.04)
Co-prescribing:
Benzodiazepines 2.73 (0.85 to 8.76) 4.35 (1.32 to 14.30)*
Antipsychotics 0.18 (0.056 to 0.58)* 0.27 (0.08 to 0.89)*
Antidepressants 0.29 (0.16 to 0.53)* 0.51 (0.30 to 0.98)*
Opioid analgesics 0.65 (0.39 to 1.10) 0.72 (0.41 to 1.26)
Final regression model mutually adjusted for all significant covariates; male sex, comorbidity (Charlson index),
social class, mean methadone dose (≥60 mg daily), and volume of methadone prescribing by practice were
assessed unadjusted but had no significant influence on cause specific mortality (P>0.2) and so were excluded
from final model.
NA=not applicable.
*P<0.05.
†Variable treated as time varying coefficient in Cox regression model and hazard ratio reported at median
follow-up of 4.38 years.
WHAT IS ALREADY KNOWN ON THIS TOPIC
Randomised controlled trials have shown that methadone
maintenance is an effective intervention, decreasing illicit
drug use, reducing injecting behaviour, and reducing opioid
related deaths
Concern exists about the safety of prescribingmethadone in
community settings, as methadone itself is associated with
drug related deaths
WHAT THIS STUDY ADDS
Overuse of methadone, history of psychiatric admission,
and increased comorbidity were associated with all cause
mortality; drug dependent deaths were associated with co-
prescription of benzodiazepines and history of psychiatric
admission
History of urine testing, longer duration of use of
methadone, and increasing time since last filled
prescriptionwere all associatedwith a reduced risk of death
Important elements in the process of care when providing
methadone maintenance in the community may influence
each person’s risk of death.
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The requirement of an evidence based approach to
methadone maintenance is well suited to implementa-
tion by means of such support systems, particularly in
relation to coordination of care and multidisciplinary
working.6 36 Computerised clinical decision support
systems would also support alternative forms of opioid
replacement treatment such as buprenorphine.37
Conclusions
This community based study shows that important ele-
ments in the process of care when providing metha-
done maintenance are likely to influence each
patient’s risk of death. Prescribing of methadone
could be improved, particularly as regards dosage,
co-prescribing of benzodiazepines, and monitoring.
Further research is needed into health information
technology systems that provide structure to the plan-
ning, coordination, and monitoring needed for an
effective methadone maintenance programme in pri-
mary care.35
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